Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor

30. juni 2016 opdateret af: Hoffmann-La Roche

An Open-label Study to Evaluate the Safety of MabThera, and Its Effect on Treatment Response, in Patients With Rheumatoid Arthritis Following Inadequate Response to a Single Anti-TNF Agent

This study will evaluate the efficacy and safety of MabThera in patients with active rheumatoid arthritis who have had an inadequate response to one prior anti-TNF alpha inhibitor. MabThera-naive patients will be stratified into 3 arms, according to previous inadequate response to a)etanercept, b)infliximab or c)adalimumab. Patients will be treated with MabThera (1g infusion) on day 1 and day 15, and will continue their basic methotrexate therapy. The anticipated time on study treatment is 2+ years, and the target sample size is 100-500 individuals.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

302

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Tyskland
      • Bad Abbach, Tyskland, 93077
      • Bad Aibling, Tyskland, 83043
      • Bad Bramstedt, Tyskland, 24576
      • Bamberg, Tyskland, 96047
      • Berlin, Tyskland, 10117
      • Berlin, Tyskland, 12200
      • Berlin, Tyskland, 13125
      • Berlin, Tyskland, 13589
      • Berlin, Tyskland, 13055
      • Berlin, Tyskland, 14163
      • Bonn, Tyskland, 53111
      • Bremen, Tyskland, 28199
      • Cuxhaven, Tyskland, 27476
      • Damp, Tyskland, 24351
      • Donaueschingen, Tyskland, 78166
      • Dresden, Tyskland, 01109
      • Düsseldorf, Tyskland, 40225
      • Düsseldorf, Tyskland, 40211
      • Erfurt, Tyskland, 99096
      • Erlangen, Tyskland, 91054
      • Erlangen, Tyskland, 91056
      • Essen, Tyskland, 45326
      • Essen, Tyskland, 45239
      • Frankfurt Am Main, Tyskland, 60590
      • Freiburg, Tyskland, 79106
      • Fulda, Tyskland, 36039
      • GIEßEN, Tyskland, 35392
      • Gommern, Tyskland, 39245
      • Göttingen, Tyskland, 37075
      • Hagen, Tyskland, 58135
      • Halle, Tyskland, 06120
      • Hamburg, Tyskland, 22081
      • Hannover, Tyskland, 30625
      • Hannover, Tyskland, 30159
      • Heidelberg, Tyskland, 69120
      • Herne, Tyskland, 44652
      • Hofheim, Tyskland, 65719
      • Homburg/saar, Tyskland, 66424
      • Jena, Tyskland, 07743
      • Karlsruhe, Tyskland, 76135
      • Köln, Tyskland, 50924
      • Ludwigshafen, Tyskland, 67063
      • Mainz, Tyskland, 55131
      • Mainz, Tyskland, 55122
      • Mittelherwigsdorf, Tyskland, 02763
      • Muenchen, Tyskland, 80336
      • Mönchengladbach, Tyskland, 41061
      • München, Tyskland, 81541
      • München, Tyskland, 80335
      • Münster, Tyskland, 48149
      • Naunhof, Tyskland, 04683
      • Oldenburg, Tyskland, 26121
      • Osnabrück, Tyskland, 49074
      • Pirna, Tyskland, 01796
      • Ratingen, Tyskland, 40882
      • Rostock, Tyskland, 18059
      • Schwerte, Tyskland, 58239
      • Sendenhorst, Tyskland, 48324
      • Stuttgart, Tyskland, 70178
      • Treuenbrietzen, Tyskland, 14929
      • Trier, Tyskland, 54292
      • Tübingen, Tyskland, 72076
      • ULM, Tyskland, 89081
      • Wiesbaden, Tyskland, 65191
      • Wiesbaden, Tyskland, 65189
      • Wuerzburg, Tyskland, 97080
      • Wuppertal, Tyskland, 42105
      • Würselen, Tyskland, 52146
      • Zeven, Tyskland, 27404

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • adult patients, 18-75 years of age;
  • rheumatoid arthritis for >=6 months;
  • previous inadequate response to a single anti-TNF alpha inhibitor;
  • methotrexate at a stable dose range 7.5-25 mg/week.

Exclusion Criteria:

  • other chronic inflammatory articular disease or systemic autoimmune disease;
  • previous treatment with MabThera or intolerance to MabThera;
  • corticosteroids>=10 mg/day prednisolone within last 2 weeks, or corticosteroids at unstable doses within last 2 weeks;

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: MabThera (Rituximab)
Medicin: rituximab [MabThera]
1 g was given by intravenous infusion on Days 1 and 15

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change From Baseline to Week 24 in Disease Activity Score Based on 28-Joint Count (DAS28)
Tidsramme: Week 24
The DAS28 consists of swollen joint count (SJC) and tender joint count (TJC) measurements, the erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hr), and the Patient's Global Assessment of Disease Activity (participant-ated rheumatoid arthritis [RA] activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 less than or equal to (≤)3.2 equals (=) low disease activity, DAS28 greater than (>)3.2 to 5.1 = moderate to high disease activity.
Week 24

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
DAS28 Score
Tidsramme: Screening and Weeks 8, 16, and 24
The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant-rated RA assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.
Screening and Weeks 8, 16, and 24
Percentage of Participants With European League Against Rheumatism (EULAR) Response of Good or Moderate
Tidsramme: Weeks 8, 16, and 24
The DAS28-based EULAR response criteria were used to measure individual responses as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders experienced a change from baseline of >1.2 with a DAS28 score ≤3.2 and moderate responders experienced a change from baseline >1.2 with DAS28 >3.2 to ≤5.1 or a change from baseline >0.6 to ≤1.2 with a DAS28 score of ≤5.1.
Weeks 8, 16, and 24
Percentage of Participants With Low Disease Activity (DAS28 ≤3.2) at Week 24
Tidsramme: Week 24
Percentage of participants with low disease activity defined as DAS28 ≤3.2 at follow-up Week 24. The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity).
Week 24
Percentage of Participants Achieving Remission (DAS28 <2.6) at Week 24
Tidsramme: Week 24
Percentage of participants with remission defined as DAS28 <2.6 at follow-up Week 24. The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.
Week 24
Percentage of Participants Achieving a Response By EULAR Category
Tidsramme: Weeks 8, 16, and 24
Percentage of participants achieving a response by EULAR category, including 'moderate', 'good', or no response at follow-up Weeks 8, 16, and 24. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline >1.2 with a DAS28 score ≤ 3.2; moderate responders had a change from baseline >1.2 with a DAS28 score of >3.2 to ≤5.1 or a change from baseline >0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders had a change from baseline ≤0.6 or change from baseline >0.6 and ≤1.2 with a DAS28 score of >5.1.
Weeks 8, 16, and 24
Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
Tidsramme: Screening and Weeks 8, 16, and 24
The HAQ-DI score consists of questions referring to 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific sub-category items. The standard disability score was calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered, yielding a score from 0 (without any difficulty) to 3 (unable to do).
Screening and Weeks 8, 16, and 24
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score
Tidsramme: Screening and Weeks 8, 16, and 24
The FACIT fatigue scale is base on a 13-item questionnaire to assess the therapy-induced fatigue. Participants were requested to score each question on a scale ranging from 0 (best) to 4 (worst). The scoring system of the FACIT fatigue scale adds up to a total scale ranging from 0 (best) to 52 (worst). The assessment was originally developed for chronic illnesses and is now validated for patients with rheumatoid arthritis (RA). The questionnaire was provided in a German translation.
Screening and Weeks 8, 16, and 24
Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS)
Tidsramme: Screening and Weeks 8, 16, and 24
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the physical and mental composite t-scores (PCS and MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.
Screening and Weeks 8, 16, and 24
SF-36 Domain Scores
Tidsramme: Screening and Weeks 8, 16, and 24
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to two distinct higher-ordered clusters: the physical and mental composite t-scores (PCS and MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.
Screening and Weeks 8, 16, and 24
Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%), 50% or 70% Response (ACR20/ACR50/ACR70)
Tidsramme: Weeks 8, 16, and 24
ACR20/50/70 response: ≥20%, ≥50%, or ≥70% improvement, respectively, in tender or swollen joint counts and ≥20%, ≥50%, or ≥70% improvement, respectively, in 3 of the following 5 criteria: 1) Physician's Global Assessment of Disease Activity, 2) Patient's Global Assessment of Disease Activity, 3) Patient's Assessment of Pain, 4) participant assessment of functional disability via a HAQ-DI, and 5) C-reactive protein or ESR at each visit.
Weeks 8, 16, and 24
Swollen Joint Count (SJC)
Tidsramme: Screening and Weeks 8, 16, and 24
The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of swollen joints, each, ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.
Screening and Weeks 8, 16, and 24
Tender Joint Count (TJC)
Tidsramme: Screening and Weeks 8, 16, and 24
The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of tender joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.
Screening and Weeks 8, 16, and 24
Physician's Global Assessment of Disease Activity
Tidsramme: Screening and Weeks 8, 16, and 24
Physicians assessed the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity).
Screening and Weeks 8, 16, and 24
Patient's Assessment of Disease Activity
Tidsramme: Screening and Weeks 8, 16, and 24
Participants were to assess the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity).
Screening and Weeks 8, 16, and 24
Patient's Assessment of Pain
Tidsramme: Screening and Weeks 8, 16, and 24
Participants were to assess their current level of pain on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand (100 mm) as "unbearable pain".
Screening and Weeks 8, 16, and 24
C-Reactive Protein (CRP)
Tidsramme: Screening, Days 1 and 15, and Weeks 8, 16, and 24
Mean CRP as measured as an acute phase reactant by mg per deciliter (mg/dL) at screening, Days 1 and 15, and Weeks 8, 16, and 24.
Screening, Days 1 and 15, and Weeks 8, 16, and 24
Erythrocyte Sedimentation Rate (ESR)
Tidsramme: Screening, Days 1 and 15, and Weeks 8, 16, and 24
Mean ESR, as an acute phase reactant, measured in mm/hr at screening, Days 1 and 15, and Weeks 8, 16, and 24.
Screening, Days 1 and 15, and Weeks 8, 16, and 24
Rheumatoid Factor (RF)
Tidsramme: Screening and Weeks 8, 16, and 24
Mean RF as measured by international unit per milliliter (IU/mL) at screening and Weeks 8, 16, and 24.
Screening and Weeks 8, 16, and 24

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Hoffmann-La Roche

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. november 2006

Primær færdiggørelse (Faktiske)

1. november 2010

Studieafslutning (Faktiske)

1. november 2010

Datoer for studieregistrering

Først indsendt

4. marts 2014

Først indsendt, der opfyldte QC-kriterier

4. marts 2014

Først opslået (Skøn)

5. marts 2014

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

29. juli 2016

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. juni 2016

Sidst verificeret

1. juni 2016

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • ML19070

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Rheumatoid arthritis

Kliniske forsøg med rituximab [MabThera]

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Chile

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

3
Abonner